You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 64 No. 12, December 2007 TABLE OF CONTENTS
  Archives
  •  Online Features
  Controversies in Neurology
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in this journal
 Topic Collections
 •Myasthenia Gravis
 •Neuroendocrinology
 •Neuromuscular diseases
 •Ophthalmology
 •Ophthalmological Disorders, Other
 •Immunologic Disorders
 •Immunology, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Treating Ocular Myasthenia Gravis With Inadequate Evidence

E. S. Roach, MD

Arch Neurol. 2007;64(12):1794-1795.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The essence of wisdom is the ability to make the right decision on the basis of inadequate evidence.—Alan Gregg

We do not know the best way to treat ocular myasthenia gravis (OMG). Every day we must recommend therapy despite the limitations of our knowledge, and the promise of a yet-to-be-completed study is not very helpful for individuals who must decide about treatment now. Gilbert et al1 and Chavis and colleagues2 agree that many patients with OMG go on to develop generalized MG (GMG) and that preventing this progression is desirable. They also agree that immunotherapy with corticosteroids or thymectomy seems to work for OMG. There is concern, however, about the risks of long-term corticosteroid therapy or a major operation, such as thymectomy, and whether these risks can be justified in an individual with only ocular symptoms. The evidence that early immunotherapy in individuals with OMG . . . [Full Text of this Article]

AUTHOR INFORMATION



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Ocular Myasthenia Gravis Treatment: The Case Against Prednisone Therapy and Thymectomy
Molly E. Gilbert, Eduardo A. De Sousa, and Peter J. Savino
Arch Neurol. 2007;64(12):1790-1792.
EXTRACT | FULL TEXT  

Immunosuppressive or Surgical Treatment for Ocular Myasthenia Gravis
Pamela S. Chavis, David E. Stickler, and Aljoeson Walker
Arch Neurol. 2007;64(12):1792-1794.
EXTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.